Advertisement

Herzinsuffizienz

  • Michael Fresenius
  • Michael Heck

Zusammenfassung

ProBNP dient auch sehr gut zur Differenzierung bei akuter Dyspnoe (keine kardiale Ursache der Dyspnoe bei geringen ProBNP-Werten!).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Ausgewählte Literatur

  1. Abraham WT, Fisher WG, Smith AL et al., for the MIRACLE Study Group (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845–1853PubMedCrossRefGoogle Scholar
  2. Anand IS, Fisher LD, Chiang YT et al., for the Val-HeFT Investigators (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283PubMedCrossRefGoogle Scholar
  3. Auricchio A et al. (1999) Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive heart failure Study Group. Circulation 99:2993–3001PubMedGoogle Scholar
  4. Bristow MR, Saxon LA, Boehmer J et al., for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140–2150PubMedCrossRefGoogle Scholar
  5. Deutsche gesellschaft fur Kardiologie (2009) Pocket-Leitlinien »Therapie der chronischen HerzinsuffizienzGoogle Scholar
  6. Cazeau S, Leclercq C, Lavergne T et al. (2001) Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344:873–880PubMedCrossRefGoogle Scholar
  7. Cohn JN, Tognoni GA, for the Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 346:1667–1675CrossRefGoogle Scholar
  8. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Suuton GC, Grobbee DE (1997) The epidemiology of heart failure. Eur Heart J 18:208–225PubMedGoogle Scholar
  9. Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J 27:1979–2030PubMedCrossRefGoogle Scholar
  10. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273:1450–1456PubMedCrossRefGoogle Scholar
  11. Granger CB, McMurray JJ, Yusuf S et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative trial. Lancet 362:772–776PubMedCrossRefGoogle Scholar
  12. Groban L, Butterworth J (2006) Perioperative Management of Chronic Heart Failure. Anesth Analg 103: 557–575PubMedCrossRefGoogle Scholar
  13. Hohnloser SH et al. (2000) Leitlinien zur Implantation von Defibrillatoren. Z Kardiol 89:126–135CrossRefGoogle Scholar
  14. Hoppe UC, Böhm M, Dietz R et al (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Im Auftrag der Deutschen Gesellschaft für Kardiologie. Z Kardiol 94: 488–509PubMedCrossRefGoogle Scholar
  15. Hoppe UC, Böhm M, Drexler H et al. (2009) Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008. Kardiologe 3: 16–23CrossRefGoogle Scholar
  16. Hoppe UC, Erdmann E (2002) Chronische Herzinsuffizienz – Stellenwert der biventrikulären Stimulation. Dtsch Med Wochenschr 127:677–681PubMedCrossRefGoogle Scholar
  17. Hoppe UC, Erdmann E, für die Kommission Klinische Kardiologie (2001) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 90:218–237PubMedCrossRefGoogle Scholar
  18. Hunt SA, Baker DW, Chin MH et al. (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Tasc Force on practice guidelines Committee to revise the 1995 guidelines for the evaluation and management of heart failure developed in collaboration with the International Society for Heart and Lung Transplantation endorsed by the Heart Failure Society of America. J Am Coll Cardiol 38:2101–2113PubMedCrossRefGoogle Scholar
  19. Kindermann M, Janzen I, Hennen B, Böhm M (2002) Chronische Herzinsuffizienz: Therapie. Dtsch Med Wochenschr 127:1139–1144PubMedCrossRefGoogle Scholar
  20. Linde C, Leclerq C, Rex S et al. (2002) Long-term benefits of biventricular pacing in congestive heart failure: results from the Multisite Stimulation In Cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40:111–118PubMedCrossRefGoogle Scholar
  21. Luchner A, Holmer S, Schunkert H, Riegger GA (2004) Bedeutung der Herzinsuffizienzmarker BNP und NT-proBNP für die Klinik. Dtsch Arztebl 100:A-3314–3321Google Scholar
  22. McMurray JJ, Ostergren J, Swedberg K et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added Trial. Lancet 362:767–771PubMedCrossRefGoogle Scholar
  23. Moss AJ, Zareba W, Hall WJ et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883PubMedCrossRefGoogle Scholar
  24. Packer M, Abraham WT (2001) Effect of cardiac resynchronisation on a composite clinical status endpoint in patients with chronic heart failure: results of the MIRACLE trial. Circulation 104:1995Google Scholar
  25. Pfeffer MA, Braunwald E, Moye LA et al., on behalf of the SAVE Investigators (1992) Effect of captopril on mortality in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327:669–677PubMedCrossRefGoogle Scholar
  26. Pfeffer MA, McMurray JJ, Velazquez EJ et al. (2003) for the Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril or both in myocardial infarction complicated by heart failure, left-ventricular dysfunction, or both. N Engl J Med 349:1893–1906PubMedCrossRefGoogle Scholar
  27. Pitt B, Zannad F, Remme WJ et al., for the Randomized Aldactone Evaluation Study Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717PubMedCrossRefGoogle Scholar
  28. Pitt B, Poole-Wilson PA, Segal R et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMedCrossRefGoogle Scholar
  29. Pitt B, Remme WJ, Zannad F, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left-ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321PubMedCrossRefGoogle Scholar
  30. Poole-Wilson PA, Swedberg K, Cleland JG et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 362:7–13PubMedCrossRefGoogle Scholar
  31. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347:1403–1411PubMedCrossRefGoogle Scholar
  32. Rauch H, Motsch J, Bottiger BW (2006) Newer approaches to the pharmacological management of heart failure. Curr Opin Anaesthesiol 19:75–81PubMedCrossRefGoogle Scholar
  33. Redfield MM (2004) Understanding »diastolic« heart failure. N Engl J Med 350:1939–1941CrossRefGoogle Scholar
  34. Schmid FX, Hengstenberg C, Völkel S, Birnbaum D (2004) Chirurgische Therapieoptionen bei schwerer Herzinsuffizienz. Dtsch Arztebl 101:A 429–435Google Scholar
  35. Schwinger RHG, Brixius K (2005) Wenn die Myofilamente sensibel werden. Ca2+-Sensitizer zur Therapie der Herzinsuffizienz. Dtsch Med Wochenschr 130: 969–973PubMedCrossRefGoogle Scholar
  36. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 29: 2388–2442CrossRefGoogle Scholar
  37. Schwinger RHG (2002) Therapie der Herzinsuffizienz mit ß-Rezeptorenblockern. Dtsch Med Wochenschr 127:682–688PubMedCrossRefGoogle Scholar
  38. The Antiarrhythmics Versus Implantable defibrillators (AVID) investigators (1997) A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576–1583CrossRefGoogle Scholar
  39. Zannad F, McMurray JJV Krum H et al. (2011) Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 364: 11–21PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Michael Fresenius
    • 1
  • Michael Heck
    • 2
  1. 1.Chefarzt der Klinik für Anästhesie und IntensivmedizinMarienhaus Klinikum Bendorf-Neuwied-WaldbreitbachNeuwied
  2. 2.Facharzt für Anästhesiologie – ambulante Narkosen –Heidelberg

Personalised recommendations